Health CanadaGeneral Alert
Increased risk of marked hepatic enzyme elevations in patients taking SOMAVERT (...
Published: June 10, 2008Recall ID: 24577Category: generalCountry: Canada
Product Description & Identification
Increased risk of marked hepatic enzyme elevations in patients taking SOMAVERT (pegvisomant) in combination with a somatostatin analogue - For Health Professionals
Additional Source Details
| Field | Value |
|---|---|
| N I D | 24577 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/increased-risk-marked-hepatic-enzyme-elevations-patients-taking-somavert-pegvisomant |
| Title | Increased risk of marked hepatic enzyme elevations in patients taking SOMAVERT (pegvisomant) in combination with a somatostatin analogue - For Health Professionals |
| Archived | 1 |
| Category | Biologic or vaccine |
| Last updated | 2008-06-10 |
| Organization | Marketed health products |